| Literature DB >> 28623350 |
Bart Cuypers1,2, Malgorzata A Domagalska1, Pieter Meysman2, Géraldine de Muylder1, Manu Vanaerschot1,3, Hideo Imamura1, Franck Dumetz1, Thomas Wolf Verdonckt1, Peter J Myler4,5, Gowthaman Ramasamy4, Kris Laukens2, Jean-Claude Dujardin6,7.
Abstract
High throughput sequencing techniques are poorly adapted for in vivo studies of parasites, which require prior in vitro culturing and purification. Trypanosomatids, a group of kinetoplastid protozoans, possess a distinctive feature in their transcriptional mechanism whereby a specific Spliced Leader (SL) sequence is added to the 5'end of each mRNA by trans-splicing. This allows to discriminate Trypansomatid RNA from mammalian RNA and forms the basis of our new multiplexed protocol for high-throughput, selective RNA-sequencing called SL-seq. We provided a proof-of-concept of SL-seq in Leishmania donovani, the main causative agent of visceral leishmaniasis in humans, and successfully applied the method to sequence Leishmania mRNA directly from infected macrophages and from highly diluted mixes with human RNA. mRNA profiles obtained with SL-seq corresponded largely to those obtained from conventional poly-A tail purification methods, indicating both enumerate the same mRNA pool. However, SL-seq offers additional advantages, including lower sequencing depth requirements, fast and simple library prep and high resolution splice site detection. SL-seq is therefore ideal for fast and massive parallel sequencing of parasite transcriptomes directly from host tissues. Since SLs are also present in Nematodes, Cnidaria and primitive chordates, this method could also have high potential for transcriptomics studies in other organisms.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28623350 PMCID: PMC5473914 DOI: 10.1038/s41598-017-03987-0
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Graphical summary of the SL-seq protocol. (A) cDNA generation with Superscript III and a primer that is partially random (7 nucleotides, grey), and partially fixed (yellow). Consequent degradation of the RNA strand with RNAse H, leaving a single stranded DNA molecule. (B) Second strand synthesis of SL-containing DNA molecules with Klenow fragment and a primer that is complementary with the SL (dark blue). (C + D) PCR for amplification and addition of adapter motives (red and purple) making the library compatible with the Nextera XT index kit (Illumina). (E + F) Final PCR adapter extension, indexing (orange and light blue) and amplification of the library fragments with the primers of the Nextera XT index kit. Dark Blue: SL/ complementary with SL, light grey: RNA, dark grey: DNA, green: poly-A tail. Other colors: primer and adapters sequences.
Figure 2(a) Relation between the raw sequencing depth per sample and the amount of detected genes. Genes were considered detected if they had at least 10 counts in every sample. Every point represents a full differential expression analysis started from a specified amount of raw sequencing reads, sampled from the original files. (b) Relation between the raw sequencing depth per sample and the amount of detected differentially expressed genes (DESEQ2 FDR Adjusted p < 0.05) between LOG and STAT Leishmania promastigotes.
Figure 3Differentially expressed genes obtained with SL-seq (SL-UP and SL-DOWN) and Illumina stranded mRNA seq methods (ILL-UP and ILL-DOWN). Genes were considered significantly upregulated if the FDR adjusted p-value was lower than 0.05 and the log2FC greater than 1. Genes were considered significantly downregulated if the FDR adjusted p-value was lower than 0.05 and the log2FC bigger smaller than −1.
Figure 4Correlation between log2 fold change obtained from sequencing with SL-seq versus Illumina stranded mRNA library prep. (a) All genes are plotted for which counts were obtained in both library preps. (b) Only genes plotted that had a significant LOG-STAT fold change (DESEQ2 adjusted p < 0.05) with both SL-Seq and ILL-Seq.
Figure 5Venn diagrams showing the overlap between SL-Seq or ILL-Seq of GO sets found downregulated (Down) or upregulated (Up) with GOA (left) and GSEA (right). Note: For both methods, no upregulated GO sets were found for ILL-Seq.
Proportion of reads mapping to respectively human and Leishmania genomes in control conditions and in samples diluted 1/100 and 1/1000 with human RNA.
| Dilution | Human |
| Theoretical enrichment | ||
|---|---|---|---|---|---|
| Average(%) | St.Dev | Average(%) | St.Dev | ||
| 0 | 0.18 | 0.05 | 96.38 | 0.58 | NA |
| 1/100 | 35.21 | 1.50 | 57.69 | 2.40 | 59.86x |
| 1/1000 | 76.40 | 0.88 | 12.44 | 0.96 | 129.07x |
The last column indicates how many times SL-seq enriched the Leishmania mRNA compared to the Illumina kit.
Relative enrichment of Leishmania mRNA with SL-sequencing from infected THP-1 monocytes.
| Sample | Infection | Illumina Stranded mRNA | SL-Seq | Enrichment (X) | ||
|---|---|---|---|---|---|---|
| %Human | % | %Human | % | |||
| 1 | NI | 98.14 | 0.06 | 84.16 | 0.55 | |
| 2 | NI | 98.09 | 0.06 | 84.60 | 0.47 | |
| 3 | BPK275 | 97.09 | 1.17 | 28.89 | 64.75 | 55.17 |
| 4 | BPK275 | 96.85 | 1.36 | 29.13 | 64.89 | 47.61 |
| 5 | BPK282 | 96.31 | 1.89 | 23.38 | 70.92 | 37.44 |
| 6 | BPK282 | 96.31 | 1.90 | 20.73 | 74.29 | 39.06 |
| Average | 44.82 ± 8.2 | |||||
THP-1 monocytes infected with Leishmania strain BPK275 and BPK282 and uninfected controls were sequenced with both SL-seq and a conventional poly-A mRNA kit (Illumina stranded mRNA). Displayed percentages show the relative amount of sequencing reads mapping to the human (hg38) and Leishmania genome with each kit. The last column indicates how many times SL-seq enriched the Leishmania mRNA compared to the Illumina kit.